{"title":"在低风险新生血管性年龄相关性黄斑变性治疗中，加载雷尼单抗对视力相关生活质量的影响。","authors":"Hatice Daldal","doi":"10.1177/25158414221108021","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The loss of central vision plays a major role in the quality of life (QoL). This study evaluates the changes in QoL in the treatment of low-risk neovascular age-related macular degeneration (AMD).</p><p><strong>Objectives: </strong>The aim of this study was to evaluate the changes in vision-related QoL in patients receiving intravitreal ranibizumab loading dose for low-risk neovascular AMD.</p><p><strong>Design: </strong>A prospective study.</p><p><strong>Methods: </strong>Forty-two eyes of 42 patients receiving ranibizumab injections for neovascular AMD were included in this prospective study. The changes in best-corrected visual acuity (BCVA), central macular thickness (CMT) of the patients before the treatment, and 1 month after three loading doses were evaluated. Turkish version of the National Eye Institute 25-Item Vision Function Questionnaire (NEI VFQ-25 TR) was conducted. The changes of QoL scores through the NEI VFQ-25 TR questionnaire were compared with visual acuity (VA) and CMT measurements before the injections and 1 month after the loading dose.</p><p><strong>Results: </strong>Forty-two patients (19 females and 23 males) were included in the study, and the mean age was 72.69 ± 7.12 years. After the treatment, a statistically significant improvement in BCVA (0.98 ± 0.44, 0.76 ± 0.42 logMAR, <i>p</i> < 0.001) and a significant decrease in CMT (357.90 ± 71.71, 274.50 ± 58.35 μm, <i>p</i> < 0.001) was observed. The QoL composite score was found to be statistically significantly higher after the treatment (64.27 ± 11.47, 68.56 ± 11.39, <i>p</i> < 0.001). General vision (<i>p</i> < 0.001), ocular pain (<i>p</i> = 0.025), near activities (<i>p</i> < 0.001), distance activities (<i>p</i> = 0.027), vision-specific mental health (<i>p</i> = 0.014), vision-specific role difficulties (<i>p</i> < 0.001), and peripheral vision (<i>p</i> = 0.046) were significantly higher after the treatment.</p><p><strong>Conclusion: </strong>NEI VFQ-25 TR is a useful questionnaire for evaluating changes in visual functions and psychosocial characteristics of low-risk neovascular AMD patients before and after the injections.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2022-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8d/8b/10.1177_25158414221108021.PMC9297452.pdf","citationCount":"0","resultStr":"{\"title\":\"The effects of loading ranibizumab on vision-related quality of life in the treatment of low-risk neovascular age-related macular degeneration.\",\"authors\":\"Hatice Daldal\",\"doi\":\"10.1177/25158414221108021\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The loss of central vision plays a major role in the quality of life (QoL). This study evaluates the changes in QoL in the treatment of low-risk neovascular age-related macular degeneration (AMD).</p><p><strong>Objectives: </strong>The aim of this study was to evaluate the changes in vision-related QoL in patients receiving intravitreal ranibizumab loading dose for low-risk neovascular AMD.</p><p><strong>Design: </strong>A prospective study.</p><p><strong>Methods: </strong>Forty-two eyes of 42 patients receiving ranibizumab injections for neovascular AMD were included in this prospective study. The changes in best-corrected visual acuity (BCVA), central macular thickness (CMT) of the patients before the treatment, and 1 month after three loading doses were evaluated. Turkish version of the National Eye Institute 25-Item Vision Function Questionnaire (NEI VFQ-25 TR) was conducted. The changes of QoL scores through the NEI VFQ-25 TR questionnaire were compared with visual acuity (VA) and CMT measurements before the injections and 1 month after the loading dose.</p><p><strong>Results: </strong>Forty-two patients (19 females and 23 males) were included in the study, and the mean age was 72.69 ± 7.12 years. After the treatment, a statistically significant improvement in BCVA (0.98 ± 0.44, 0.76 ± 0.42 logMAR, <i>p</i> < 0.001) and a significant decrease in CMT (357.90 ± 71.71, 274.50 ± 58.35 μm, <i>p</i> < 0.001) was observed. The QoL composite score was found to be statistically significantly higher after the treatment (64.27 ± 11.47, 68.56 ± 11.39, <i>p</i> < 0.001). General vision (<i>p</i> < 0.001), ocular pain (<i>p</i> = 0.025), near activities (<i>p</i> < 0.001), distance activities (<i>p</i> = 0.027), vision-specific mental health (<i>p</i> = 0.014), vision-specific role difficulties (<i>p</i> < 0.001), and peripheral vision (<i>p</i> = 0.046) were significantly higher after the treatment.</p><p><strong>Conclusion: </strong>NEI VFQ-25 TR is a useful questionnaire for evaluating changes in visual functions and psychosocial characteristics of low-risk neovascular AMD patients before and after the injections.</p>\",\"PeriodicalId\":23054,\"journal\":{\"name\":\"Therapeutic Advances in Ophthalmology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2022-07-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8d/8b/10.1177_25158414221108021.PMC9297452.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Ophthalmology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/25158414221108021\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/25158414221108021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:中心视力的丧失对生活质量(QoL)起着重要的作用。本研究评估低危新生血管性年龄相关性黄斑变性(AMD)治疗后生活质量的变化。目的:本研究的目的是评估低风险新生血管性AMD患者接受雷尼珠单抗玻璃体内负荷剂量后视力相关生活质量的变化。设计:前瞻性研究。方法:42例接受雷尼珠单抗注射治疗新生血管性AMD的患者的42只眼睛被纳入这项前瞻性研究。观察患者治疗前及三次负荷后1个月最佳矫正视力(BCVA)、黄斑中央厚度(CMT)的变化。采用土耳其语版国家眼科研究所25项视力功能问卷(NEI VFQ-25 TR)。将NEI VFQ-25 TR问卷中生活质量评分的变化与注射前和加载剂量后1个月的视力(VA)和CMT测量值进行比较。结果:共纳入42例患者，其中女性19例，男性23例，平均年龄72.69±7.12岁。治疗后，治疗后BCVA(0.98±0.44,0.76±0.42 logMAR, p p p p = 0.025)、近距离活动(p p = 0.027)、视觉特异性心理健康(p = 0.014)、视觉特异性角色困难(p p = 0.046)的改善有统计学意义。结论:NEI VFQ-25 TR是评价低危新生血管性AMD患者注射前后视觉功能和心理社会特征变化的有效问卷。
The effects of loading ranibizumab on vision-related quality of life in the treatment of low-risk neovascular age-related macular degeneration.
Background: The loss of central vision plays a major role in the quality of life (QoL). This study evaluates the changes in QoL in the treatment of low-risk neovascular age-related macular degeneration (AMD).
Objectives: The aim of this study was to evaluate the changes in vision-related QoL in patients receiving intravitreal ranibizumab loading dose for low-risk neovascular AMD.
Design: A prospective study.
Methods: Forty-two eyes of 42 patients receiving ranibizumab injections for neovascular AMD were included in this prospective study. The changes in best-corrected visual acuity (BCVA), central macular thickness (CMT) of the patients before the treatment, and 1 month after three loading doses were evaluated. Turkish version of the National Eye Institute 25-Item Vision Function Questionnaire (NEI VFQ-25 TR) was conducted. The changes of QoL scores through the NEI VFQ-25 TR questionnaire were compared with visual acuity (VA) and CMT measurements before the injections and 1 month after the loading dose.
Results: Forty-two patients (19 females and 23 males) were included in the study, and the mean age was 72.69 ± 7.12 years. After the treatment, a statistically significant improvement in BCVA (0.98 ± 0.44, 0.76 ± 0.42 logMAR, p < 0.001) and a significant decrease in CMT (357.90 ± 71.71, 274.50 ± 58.35 μm, p < 0.001) was observed. The QoL composite score was found to be statistically significantly higher after the treatment (64.27 ± 11.47, 68.56 ± 11.39, p < 0.001). General vision (p < 0.001), ocular pain (p = 0.025), near activities (p < 0.001), distance activities (p = 0.027), vision-specific mental health (p = 0.014), vision-specific role difficulties (p < 0.001), and peripheral vision (p = 0.046) were significantly higher after the treatment.
Conclusion: NEI VFQ-25 TR is a useful questionnaire for evaluating changes in visual functions and psychosocial characteristics of low-risk neovascular AMD patients before and after the injections.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
